Date: 2017-09-06
Type of
information: Recruitment of the first patient
phase: 1
Announcement: recruitment of the first patient
Company: Daiichi Sankyo (Japan) Sanford Burnham Prebys Medical Discovery Institute (USA - CA)
Product: DS-1211
Action
mechanism:
- DS-1211 targets Tissue Non-Specific Alkaline Phosphatase (TNAP). This first-in-class small molecule has been jointly developed through a research collaboration between Daiichi Sankyo and SBP, which resulted from a strategic alliance the two organizations initiated in 2014. Foundational science for DS-1211 comes from pioneering research by José Luis Millán, Ph.D., professor at SBP, whose work has led to a molecular and cellular understanding of how calcification is primarily controlled.
Disease:
Therapeutic
area:
Country:
Trial
details:
Latest
news:
- • On September 6, 2017, Daiichi Sankyo and Sanford Burnham Prebys Medical Discovery Institute (SBP) announced the enrollment of the first patient in a phase 1, first-in-human clinical trial of DS-1211 in healthy volunteers.
Is
general: Yes
